In , Advanced Enzyme Technologies Ltd (Seeds/Tissue Culture/Bio Technology) is outperforming Nifty 500 with +25.6% relative strength. Fundamentals: Average. On a 4-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 19, 2026
What: Asia Revenue Growth: Stupendous
“The work which we did in the last two, three, four years, they are yielding some results right now, and we can see that there is certain growth in the Asia.”
What: Product Approvals: 9 products in EU
“If that works out, then probably, the Europe business can grow much faster. ... we are registering our few products in the EFSA.”
What: B2C Sales: ₹1 crore to ₹1.5 crore
“This year, probably, we'll be hitting somewhere around INR 1 CR to INR 1.5 CR ... we are separating that arm from Advanced Enzymes to the new company.”
Earnings deceleration risks from management commentary
Trigger: The imposition of U.S. tariffs has led to a shift in market dynamics and customer hesitation in placing new orders.
Impact: PAT impact: ₹7 crore to ₹8 crore
Management view: Passing on costs to customers and exploring alternative sourcing/origination strategies.
Monitor: geopolitical
Trigger: Supply chain disruptions and cost increases in China are being passed through to the industry.
Management view: Trying to pass on costs a little bit at a time to consumers.
Monitor: commodity
Key quotes from recent conference calls
“What I would say is that we will still stick with the numbers and the initial guidance what we have given that we will have this year, like, a mid-double digit growth. [Previous Revenue Growth guidance]”
“To begin with, we'll be targeting mostly on the strain development, protein engineering and on the fermentation side. That will be the first phase. [Initiative: New R&D Center in Nashik]”
“The global markets are experiencing considerable disruption due to the imposition of U.S. tariffs, leading to the shift in market dynamics. [Risk (geopolitical): HIGH]”
“Second part is the cost, which is coming out from the China on all the raw materials for packaging, shipping, etc. It is going up. [Risk (commodity): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹1,719 million
Why: Growth was mixed as several businesses delivered healthy growth while others remained flat due to global market disruptions from U.S. tariffs.
Revenue growth slowed significantly compared to the 26% YoY growth seen in the previous quarter.
EBITDA
₹494 million
Why: EBITDA was impacted by lower sales in the high-margin Human Healthcare segment and increased costs related to U.S. tariffs.
Margins contracted by 400 bps YoY as the company absorbed some tariff impacts.
PAT
₹432 million
Why: Profitability was supported by a 10% increase in profit before tax despite the operational EBITDA decline.
PAT growth remained positive YoY despite the EBITDA contraction, aided by higher other income or lower tax provisions.
Other Highlights
• Human Healthcare revenue declined 6% YoY to ₹962 million.
• Animal Healthcare revenue grew 22% YoY to ₹241 million.
• Bioprocessing segment recorded 13% YoY growth reaching ₹255 million.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Human Healthcare % of Total Revenue
56%
Why: De-growth due to lower sales in Pharma, API, and Nutrition business.
Anti-inflammatory Enzyme % of Revenue
21%
Why: Remains the largest product category with steady contribution.
R&D Spend % of Revenue
3.2%
Why: Spending remains consistent in absolute terms but varies as a percentage of revenue.
Top 10 Customer Concentration
26%
Why: Customer concentration remains stable.
India Revenue (9 Months)
₹1,710 million
International Revenue (9 Months)
₹1,686 million
Animal Healthcare % of Revenue
14%
Why: Strong growth driven by past efforts in the segment.
Specialized Manufacturing % of Revenue
9%
Why: Segment remained flat YoY and degrew sequentially due to headwinds.
Forward-looking targets from management for 3 to 5 years
Revenue Growth Target
13%
OPM Guidance
30–32%
Capex Plan
₹50 Cr
13% to 15% double digit growth
REAFFIRMED
₹50 crore
Capacity expansion
Guidance Changes
EBITDA Margin Impact from Tariffs: 200 bps → 100 bps
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +22% | +11% | Stable |
| PAT (Net Profit) | +67% | +19% | Stable |
| OPM | 31.0% | +400 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Advanced Enzyme Technologies Ltd's latest quarterly results (Mar 2026) show
Advanced Enzyme Technologies Ltd's profit is growing with an stable trend.
Advanced Enzyme Technologies Ltd's revenue growth trend is stable.
Advanced Enzyme Technologies Ltd's operating margin is volatile.
Advanced Enzyme Technologies Ltd's long-term compounding rates
Advanced Enzyme Technologies Ltd's earnings growth is stable with mixed signals on a sequential basis.
Advanced Enzyme Technologies Ltd's trailing twelve month (TTM) performance
Advanced Enzyme Technologies Ltd appears significantly overvalued based on our fair value analysis.
Advanced Enzyme Technologies Ltd's current PE ratio is 24.9x.
Advanced Enzyme Technologies Ltd's current PE is 24.9x.
Advanced Enzyme Technologies Ltd's price-to-book ratio is 2.5x.
Advanced Enzyme Technologies Ltd is rated Average with a fundamental score of 56.53/100. This score is calculated from objective financial metrics
Advanced Enzyme Technologies Ltd has a debt-to-equity ratio of N/A.
Advanced Enzyme Technologies Ltd's return ratios over recent years
Advanced Enzyme Technologies Ltd's operating cash flow is positive (FY2026).
Advanced Enzyme Technologies Ltd's current dividend yield is 1.46%.
Advanced Enzyme Technologies Ltd's shareholding pattern (Mar 2026)
Advanced Enzyme Technologies Ltd's promoter holding has increased recently.
Advanced Enzyme Technologies Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Advanced Enzyme Technologies Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Advanced Enzyme Technologies Ltd has 3 key growth catalysts identified from recent earnings analysis
Advanced Enzyme Technologies Ltd has 2 key risks worth monitoring
In Q3 FY26, Advanced Enzyme Technologies Ltd's management highlighted
Advanced Enzyme Technologies Ltd's management has provided the following forward guidance for 3 to 5 years
Advanced Enzyme Technologies Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Advanced Enzyme Technologies Ltd may be worth studying
Advanced Enzyme Technologies Ltd investment thesis summary:
Advanced Enzyme Technologies Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
